-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
-
Summary
-
ArriVent BioPharma, Inc. quarterly Liabilities, Current history and growth rate from Q4 2023 to Q2 2024.
- ArriVent BioPharma, Inc. Liabilities, Current for the quarter ending June 30, 2024 was $12.1M.
Liabilities, Current, Quarterly (USD)